2019年冠状病毒病(COVID-19)
医学
随机对照试验
病毒释放
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
安慰剂
不利影响
冠状病毒
大流行
传输(电信)
入射(几何)
临床试验
内科学
病毒学
疾病
病毒
病理
物理
替代医学
光学
传染病(医学专业)
电气工程
工程类
作者
Xulin Guo,Xing Liu,Yunfu Wu,Mingming Wang,Shuo Wu,Li Guo,Zifeng Wang,Zhihong Shi,Rui Huang,Hua Zhang,Xiaona Niu,Mingzhe Rong,Liqiang Song,Dingxin Liu
标识
DOI:10.1002/ppap.202300195
摘要
Abstract Shortening the duration of the viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is critical to controlling viral transmission, alleviating the burden on the healthcare system, and ultimately mitigating the impact of the pandemic. This randomized, single‐blind, placebo‐controlled clinical trial aimed to investigate the safety and efficacy of gargling with plasma‐activated water (PAW) on prolonged viral shedding in patients infected with SARS‐CoV‐2 Delta and Omicron variants. Sixty‐two subjects, aged 18–80 years and infected with SARS‐CoV‐2, were recruited at two coronavirus disease 2019 (COVID‐19)‐designated hospitals in Shaanxi from January to March 2022. Primary outcomes included cumulative conversion rates, incidence of adverse reactions, and biosafety parameters. Results suggested that PAW gargling treatment might contribute to reducing the duration of SARS‐CoV‐2 Delta and Omicron variant infections and alleviating symptoms.
科研通智能强力驱动
Strongly Powered by AbleSci AI